drugset / Trial / NCT05352828
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.
Timeline
- Start
- 2022-07-25
- Primary completion
- 2025-12-15
- Completion
- 2037-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD30.CAR-T | Cell therapy | 2e+08 unknown | — |
| Subject | Nivolumab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Background | Bendamustine | Small molecule | 70 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |